Turnstone Biologics Corp. (TSBX) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
9310 Athena Circle
LA Jolla, CA 92037
United States of America (the)
Phone
347-897-5988
Website
Sector
Healthcare
Industry
Biotechnology
Employees
14
First IPO Date
July 21, 2023
| Name | Title | Pay | Year Born |
| Sammy J. Farah | President, Chief Executive Officer & Director | 631,450 | 1973 |
| Saryah Azmat | Chief Operating Officer & Corporate Secretary | 426,900 | 1990 |
| Michael Fitch | Senior Vice President of Manufacturing | 0 | N/A |
| Wendy Worcester | Vice President, Principal Finance & Accounting Officer | 0 | N/A |
| David Stojdl | Senior Vice President of Research & Discovery | 0 | N/A |
| Ines Verdon | Senior Vice President of Clinical Development | 0 | N/A |
| Michael F. Burgess | Executive Director | 0 | 1963 |
Turnstone Biologics Corp. is a clinical-stage biotechnology firm dedicated to developing therapeutic and curative treatments for patients battling solid tumor cancers. Its leading investigational drug, TIDAL-01, is currently undergoing Phase 1 clinical trials for indications such as breast cancer, colorectal cancer, and uveal melanoma. This compound is also being assessed in an investigator-sponsored trial to address cutaneous and non-cutaneous melanomas. Furthermore, the company is advancing TIDAL-02, which is in preclinical development for treating various solid tumors. Turnstone Biologics was established in 2014 and maintains its headquarters in La Jolla, California.